Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:sec><jats:title>Objective</jats:title><jats:p>Activating glucokinase (<jats:italic>GCK</jats:italic>) mutations are a rarely reported cause of congenital hyperinsulinism (CHI), but the prevalence of <jats:italic>GCK</jats:italic> mutations is not known.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>From a pooled cohort of 201 non-syndromic children with CHI from three European referral centres (Denmark, <jats:italic>n</jats:italic>=141; Norway, <jats:italic>n</jats:italic>=26; UK, <jats:italic>n</jats:italic>=34), 108 children had no K<jats:sub>ATP</jats:sub>-channel (<jats:italic>ABCC8</jats:italic>/<jats:italic>KCNJ11</jats:italic>) gene abnormalities and were screened for <jats:italic>GCK</jats:italic> mutations. Novel <jats:italic>GCK</jats:italic> mutations were kinetically characterised.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In five patients, four heterozygous <jats:italic>GCK</jats:italic> mutations (S64Y, T65I, W99R and A456V) were identified, out of which S64Y was novel. Two of the mutations arose <jats:italic>de novo</jats:italic>, three were dominantly inherited. All the five patients were medically responsive. In the combined Danish and Norwegian cohort, the prevalence of GCK-CHI was estimated to be 1.2% (2/167, 95% confidence interval (CI) 0–2.8%) of all the CHI patients. In the three centre combined cohort of 72 medically responsive children without K<jats:sub>ATP</jats:sub>-channel mutations, the prevalence estimate was 6.9% (5/72, 95% CI 1.1–12.8%). All activating <jats:italic>GCK</jats:italic> mutations mapped to the allosteric activator site. The novel S64Y mutation resulted in an increased affinity for the substrate glucose (S<jats:sub>0.5</jats:sub> 1.49±0.08 and 7.39±0.05 mmol/l in mutant and wild-type proteins respectively), extrapolating to a relative activity index of ∼22 compared with the wild type.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In the largest study performed to date on <jats:italic>GCK</jats:italic> in children with CHI, <jats:italic>GCK</jats:italic> mutations were found only in medically responsive children who were negative for <jats:italic>ABCC8</jats:italic> and <jats:italic>KCNJ11</jats:italic> mutations. The estimated prevalence (∼7%) suggests that screening for activating <jats:italic>GCK</jats:italic> mutations is warranted in those patients.</jats:p></jats:sec>

Original publication

DOI

10.1530/eje-08-0203

Type

Journal article

Journal

European Journal of Endocrinology

Publisher

Bioscientifica

Publication Date

07/2008

Volume

159

Pages

27 - 34